NGM Biopharmaceuticals
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for liver diseases, cardiometabolic conditions, rare genetic disorders, oncology, and ophthalmic diseases. The company focuses on understanding key biological pathways to create first-in-class medicines. Key programs include aldafermin for primary sclerosing cholangitis (PSC) and NGM120 for hyperemesis gravidarum. Following its take-private transaction in April 2024, NGM is now a privately held subsidiary of Atlas Neon Parent, Inc., an affiliate of The Column Group.
Public Company
NGM Biopharmaceuticals is publicly traded
IPO'd on April 8, 2019
This company is no longer available on our private secondary market. Shares can be traded publicly under NGM.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Employees
100–150
Total Funding
$513.5M
7 rounds
Funding
Total raised $513.5M across 7 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series A (post take-private)
Date
2024
Amount
$122M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| 2024 | Series A (post take-private) | $122M | — | The Column Group |
| April 4, 2019 | IPO + PIPE | $178M | — | NASDAQ + Merck PIPE |
| March 25, 2015 | Series D-2 (Merck) | $106M | — | Merck |
Leadership
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Intercept Pharmaceuticals
Develops bile acid therapeutics for primary sclerosing cholangitis and other rare liver diseases; primary competitor in PSC drug development.
Gilead Sciences
Large pharma with programs in liver disease and fibrosis therapeutics; competitor in hepatology space.
Rhythm Pharmaceuticals
Clinical-stage biotech focused on cardiometabolic diseases and genetic disorders.
Novo Nordisk
Large pharma leader in cardiometabolic therapeutics including GLP-1 agonists for obesity and diabetes.
NGM Biopharmaceuticals Investment FAQ
NGM Biopharmaceuticals FAQ
Yes, NGM Biopharmaceuticals is publicly traded under the ticker symbol NGM on the NASDAQ. The company went public in April 8, 2019.
NGM Biopharmaceuticals trades under the ticker symbol NGM on the NASDAQ. It began trading in April 8, 2019.
NGM Biopharmaceuticals (NGM on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker NGM to place an order.
NGM Biopharmaceuticals went public in April 8, 2019 via ipo. NGM Biopharmaceuticals was a public company traded on NASDAQ under ticker NGM from April 2019 to April 2024. The company was taken private on April 5, 2024, in a $135 million cash acquisition by The Column Group at $1.55 per share. The stock had declined significantly from its IPO price of $16 to below $1 by October 2023, prompting NASDAQ delisting threats. Following privatization, NGM raised a $122 million Series A in July 2024 to fund registrational trials for aldafermin in primary sclerosing cholangitis and Phase 2 trials for NGM120 in hyperemesis gravidarum.
NGM Biopharmaceuticals raised $513.5M across 7 disclosed funding rounds prior to its public listing.
NGM Biopharmaceuticals was founded by Jin-Long Chen in 2008.
NGM Biopharmaceuticals is headquartered in South San Francisco, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.